Arteris VP & general counsel Paul Alpern sells $83,063 in shares

Paul L. Alpern, Vice President and General Counsel at Arteris, Inc., divested 4,000 shares of the company's stock on September 1, 2026, earning roughly $83,063. The shares were disposed at a price fluctuating between $20.61 and $21.38. This action was carried out under a predetermined 10b5-1 trading plan approved on February 23, 2026.

The timing coincided with a 12% decrease in the stock price over the past week, although the stock's value has increased by 134% over the past year. On the same day, Alpern bought 4,000 shares of Arteris common stock by exercising incentive stock options at $0.56 per share, leading to a total expenditure of $2,240. Following these trades, Alpern directly owned 70,733 shares of Arteris common stock.

The purchase of shares stemmed from the exercise of incentive stock options, with 49,000 options still in his direct beneficial ownership. The options had a vesting schedule wherein 25% of the total shares were granted on August 26, 2020, and subsequently, 1/48th of the total shares were granted monthly for three years, beginning on September 26, 2020.

A study by InvestingPro indicates that the stock is currently overvalued, and subscribers have access to 13 additional ProTips along with in-depth Pro Research Reports covering AIP and over 1,400 other US equities. Recently, Arteris Inc. reported a second-quarter 2026 revenue of $24.1 million, surpassing Wall Street's estimate of $22.0 million.

However, the company reported a loss of $0.10 per share, which exceeded the estimated loss of $0.06. Despite the revenue beat, Arteris' annual contract value plus royalties reached a record $99.5 million, a 44% increase year over year. Moreover, trailing 12-month royalties climbed 65% to a record $8.6 million, while remaining performance obligations reached an all-time high of $135 million.

These results prompted the company to raise its full-year revenue guidance, anticipating non-GAAP operating profit as early as the fourth quarter. In response, Jefferies upgraded Arteris’ stock rating to Buy from Hold and raised its price target to $50.00 from $35.00, expressing growing confidence in Arteris' path to non-GAAP profitability, projected to commence in the fourth quarter of 2026.